Literature DB >> 34307746

Multiculturalism: A Challenge for Cognitive Screeners in Parkinson's Disease.

Marta Statucka1, Kirsten Cherian2,3, Alfonso Fasano1,4,5, Renato P Munhoz1,4,5, Melanie Cohn1,6.   

Abstract

BACKGROUND: The Montreal Cognitive Assessment (MoCA) and the Dementia Rating Scale-2 (DRS-2) are recommended screeners for Parkinson's disease mild cognitive impairment (PD-MCI). Cross-cultural studies examining their diagnostic precision have not addressed cultural bias in a multicultural setting.
OBJECTIVES: To compare DRS-2 and MoCA performance between patients born in Canada, the USA, and the UK (Anglosphere group) and immigrant patients born elsewhere (International group). To identify sources of cultural bias by comparing group characteristics, and by assessing the relationships between performance and immigration and socio-development variables. To examine the diagnostic precision of both tools in detecting PD-MCI in each group.
METHODS: We conducted a clinical chart review of advanced PD patients who completed cognitive screeners (MoCA: n = 288, 30% International group; DRS-2: n = 426, 31% International group). All completed a comprehensive neuropsychological assessment to apply Level II PD-MCI diagnostic criteria.
RESULTS: The International group performed worse than the Anglosphere group on the MoCA and DRS-2, and the only variable that accounted for some of the group difference was the Historical Index of Human Development, a societal variable, which fully mediated the group effect on the DRS-2. Diagnostic precision of the MoCA was at chance level in the International group, and was poorer than that of the DRS-II in this group and that of the MoCA in the Anglosphere group, although these were considered poor.
CONCLUSIONS: Our results support the recommendation to exert caution in using cognitive screeners to capture PD-MCI in all patients and particularly with first generation immigrants.
© 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Dementia Rating Scale; Montreal Cognitive Assessment; immigrants; mild cognitive impairment

Year:  2021        PMID: 34307746      PMCID: PMC8287166          DOI: 10.1002/mdc3.13240

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  47 in total

1.  Luria in Uzbekistan: the vicissitudes of cross-cultural neuropsychology.

Authors:  V Nell
Journal:  Neuropsychol Rev       Date:  1999-03       Impact factor: 7.444

2.  Cognitive Advantages in Adult Turkish Bilingual Immigrants - a Question of the Chicken or the Egg.

Authors:  T Rune Nielsen; Eleonor Antelius; Gunhild Waldemar
Journal:  J Cross Cult Gerontol       Date:  2019-06

3.  An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.

Authors:  P Uysal-Cantürk; H A Hanağası; B Bilgiç; H Gürvit; M Emre
Journal:  Eur J Neurol       Date:  2017-10-16       Impact factor: 6.089

4.  Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia.

Authors:  Evelyne Matteau; Nicolas Dupré; Mélanie Langlois; Pierre Provencher; Martine Simard
Journal:  J Geriatr Psychiatry Neurol       Date:  2012-06       Impact factor: 2.680

5.  Measuring mild cognitive impairment in patients with Parkinson's disease.

Authors:  Connie Marras; Melissa J Armstrong; Christopher A Meaney; Susan Fox; Brandon Rothberg; William Reginold; David F Tang-Wai; David Gill; Paul J Eslinger; Cindy Zadikoff; Nancy Kennedy; Fred J Marshall; Mark Mapstone; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; Sarah Duff-Canning
Journal:  Mov Disord       Date:  2013-03-20       Impact factor: 10.338

6.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

7.  Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease.

Authors:  Gisela Llebaria; Javier Pagonabarraga; Jaime Kulisevsky; Carmen García-Sánchez; Berta Pascual-Sedano; Alexandre Gironell; Mercè Martínez-Corral
Journal:  Mov Disord       Date:  2008-08-15       Impact factor: 10.338

8.  Accuracy of Two Cognitive Screening Tools to Detect Mild Cognitive Impairment in Parkinson's Disease.

Authors:  Emmie W Koevoets; Ben Schmand; Gert J Geurtsen
Journal:  Mov Disord Clin Pract       Date:  2018-03-23

9.  Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests.

Authors:  Angela Federico; Alice Maier; Greta Vianello; Daniela Mapelli; Michela Trentin; Giampietro Zanette; Alessandro Picelli; Marialuisa Gandolfi; Stefano Tamburin
Journal:  Parkinsons Dis       Date:  2015-11-08

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.